Newron presents H1 2026 results and corporate update
Newron announced its financial results and operational highlights for the first half of 2026, including that topline 12-week results for its evenamide ENIGMA-TRS 1 study are expected in Q1 2027. The company also signed a financing agreement for up to EUR 38 million.